HRP20140257T4 - Uporaba ciklesonida za liječenje bolesti dišnih puteva - Google Patents
Uporaba ciklesonida za liječenje bolesti dišnih puteva Download PDFInfo
- Publication number
- HRP20140257T4 HRP20140257T4 HRP20140257TT HRP20140257T HRP20140257T4 HR P20140257 T4 HRP20140257 T4 HR P20140257T4 HR P20140257T T HRP20140257T T HR P20140257TT HR P20140257 T HRP20140257 T HR P20140257T HR P20140257 T4 HRP20140257 T4 HR P20140257T4
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- ciclesonide
- diene
- dione
- dose
- Prior art date
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims 11
- 229960003728 ciclesonide Drugs 0.000 title claims 11
- 238000011282 treatment Methods 0.000 title claims 2
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- -1 cyclohexylmethylene Chemical group 0.000 claims 3
- 239000003999 initiator Substances 0.000 claims 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 2
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000001 growth retardation Toxicity 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (18)
1. Uporaba ciklesonida, njegove farmaceutski prihvatljive soli ili solvata, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju astme kod pacijenta, pri čemu pacijent je dijete, dok se smanjuje ili izbjegava zastoj u rastu koji je popratna pojava povezana s inhaliranim i intranazalno unesenim kortikosteroidima, i pritom je lijek prikladan za davanje putem inhalacije i primjenjuje se u dnevnoj dozi od 20 do 200µg ciklesonida u neprekidnom režimu liječenja.
2. Uporaba prema patentnom zahtjevu 1, naznačena time, da dijete je čovjek u predpubertetu.
3. Uporaba prema patentnom zahtjevu 1, naznačena time, da dijete je čovjek u dobi od 6 do 12 godina.
4. Uporaba prema patentnom zahtjevu 1, naznačena time, da se lijek primjenjuje u dozi od 20, 40, 60, 80, 100, 120, 140, 160, 180 ili 200µg ciklesonida.
5. Uporaba prema patentnom zahtjevu 1, naznačena time, da se lijek primjenjuje u dozi od 40, 80, 160µg ciklesonida.
6. Uporaba prema patentnom zahtjevu 1, naznačena time, da ona nema utjecaja na brzinu rasta pacijenta.
7. Uporaba prema patentnom zahtjevu 1, naznačena time, da lijek sadrži farmaceutski prihvatljiv nosač i/ili jedno ili više pomoćnih sredstava.
8. Uporaba prema patentnom zahtjevu 1, naznačena time, da se ciklesonid bira iz skupine od: [11β, 16α-(R)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-oksopropoksi)pregna-1,4-dien-3,20-dion,
[11β, 16α-(S)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-ksopropoksi)pregna-1,4-dien-3,20- dion,
[11β, 16α-(R,S)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-oksopropoksi)pregna-1,4-dien- 3,20-dion,
16α,17-(22R)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion,
16α,17-(22S)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion, i
16α,17-(22R,S)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion.
9. Uporaba prema patentnom zahtjevu 1, 4 ili 5, naznačena time, da doza je dnevna doza koja se primjenjuje jednom dnevno.
10. Uporaba prema patentnom zahtjevu 1, naznačena time, da pripravak je farmaceutska aerosolna formulacija koja sadrži terapijski djelotvornu količinu ciklesonida i hidrofluorokarbonski pokretač, poželjno odabran od 1,1,1,2- tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihove mješavine, te kootapalo u djelotvornoj količini za rastapanje ciklesonida i opcijski surfaktant.
11. Uporaba prema patentnom zahtjevu 10, naznačena time, da kootapalo jest etanol.
12. Uporaba prema patentnom zahtjevu 1, naznačena time, da pripravak je farmaceutska aerosolna formulacija koja sadrži čestice ciklesonida u terapijski djelotvornoj količini i hidrofluorokarbonski pokretač, poželjno odabran od 1,1,1,2- tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihove mješavine, te polarno kootapalo i opcijski surfaktant u količini od 0,01 do 5 % po masi na temelju pokretača.
13. Uporaba prema patentnom zahtjevu 1, naznačena time, da pripravak je suhi prašak i nosač je saharid.
14. Uporaba prema patentnom zahtjevu 1, naznačena time, da nosač je monohidrat laktoze.
15. Uporaba prema patentnom zahtjevu 1, naznačena time, da astma je blaga ili umjerena astma.
16. Uporaba prema patentnom zahtjevu 1, naznačena time, da se ciklesonid u biti sastoji od R epimera.
17. Uporaba prema patentnom zahtjevu 1, naznačena time, da dijete je čovjek u dobi ispod 18 godina.
18. Uporaba prema patentnom zahtjevu 11, naznačena time, da se doza pripravka daje jednom dnevno i sadrži 40, 80 ili 160µg ciklesonida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50298403P | 2003-09-16 | 2003-09-16 | |
| EP04766791.0A EP1670482B2 (en) | 2003-09-16 | 2004-09-15 | Use of ciclesonide for the treatment of respiratory diseases |
| PCT/EP2004/052172 WO2005025578A1 (en) | 2003-09-16 | 2004-09-15 | Use of ciclesonide for the treatment of respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20140257T1 HRP20140257T1 (hr) | 2014-04-25 |
| HRP20140257T4 true HRP20140257T4 (hr) | 2022-11-25 |
Family
ID=34312429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140257TT HRP20140257T4 (hr) | 2003-09-16 | 2014-03-18 | Uporaba ciklesonida za liječenje bolesti dišnih puteva |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8371292B2 (hr) |
| EP (1) | EP1670482B2 (hr) |
| JP (2) | JP5618452B2 (hr) |
| AU (1) | AU2004271744B2 (hr) |
| CA (1) | CA2538419C (hr) |
| DK (1) | DK1670482T4 (hr) |
| ES (1) | ES2452691T5 (hr) |
| HR (1) | HRP20140257T4 (hr) |
| PL (1) | PL1670482T5 (hr) |
| PT (1) | PT1670482E (hr) |
| WO (1) | WO2005025578A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE405275T1 (de) * | 2002-12-12 | 2008-09-15 | Nycomed Gmbh | Kombinationsarzneimittel aus r,r-formoterol und ciclesonide |
| CA2538419C (en) * | 2003-09-16 | 2012-07-03 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| EP1720577A2 (en) * | 2004-02-27 | 2006-11-15 | Altana Pharma AG | Ciclesonide and glycopyrronium combination |
| WO2005102354A1 (en) * | 2004-04-20 | 2005-11-03 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
| WO2007092574A2 (en) * | 2006-02-08 | 2007-08-16 | Sicor, Inc. | Crystalline forms of ciclesonide |
| KR20100072295A (ko) * | 2007-10-25 | 2010-06-30 | 머크 프로스트 캐나다 리미티드 | 병용 요법 |
| ES2471145T3 (es) * | 2009-03-09 | 2014-06-25 | Mikasa Seiyaku Co,. Ltd. | Compuesto esteroide |
| AU2012296880A1 (en) | 2011-08-18 | 2014-03-27 | Astrazeneca Ab | Pharmaceutical aerosol product for administration by oral or nasal inhalation |
| NZ706573A (en) | 2012-12-21 | 2019-11-29 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for the treatment of airway disease in horses |
| LT2934544T (lt) | 2012-12-21 | 2019-02-25 | Boehringer Ingelheim Vetmedica Gmbh | Farmacinė kompozicija, apimanti ciklezonidą |
| KR102618119B1 (ko) | 2014-06-18 | 2023-12-27 | 베링거잉겔하임베트메디카게엠베하 | 말의 기도 질환의 치료를 위한 무스카린 길항제 및 이의 병용물 |
| CN109219463B (zh) * | 2016-03-24 | 2021-05-11 | 阿诺尔德·琼·兹杜卡医疗服务有限公司 | 用于将颗粒输送到上呼吸道中的装置和方法 |
| PL3464318T3 (pl) | 2016-06-02 | 2021-11-08 | Abbvie Inc. | Agonista receptora glukokortykoidowego i jego immunokoniugaty |
| US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3166396D1 (en) | 1980-02-27 | 1984-11-08 | Tate & Lyle Plc | Crystalline glucose and process for its production |
| US4816445A (en) | 1984-06-21 | 1989-03-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline alpha-maltose |
| JP2518646B2 (ja) | 1987-05-29 | 1996-07-24 | 株式会社 林原生物化学研究所 | マルト−ス粉末の製造方法 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| DE407028T1 (de) | 1989-05-31 | 1994-03-17 | Fisons Plc | Medikament und Inhalationsvorrichtung dafür. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| SE8903914D0 (sv) | 1989-11-22 | 1989-11-22 | Draco Ab | Oral composition for the treatment of inflammatory bowel diseases |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
| DE69109284T2 (de) | 1990-03-23 | 1995-08-24 | Minnesota Mining & Mfg | Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe. |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5434304A (en) | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
| CA2094266C (en) | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
| US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US6866839B2 (en) | 1991-04-05 | 2005-03-15 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| PT656207E (pt) | 1991-06-10 | 2001-11-30 | Schering Corp | Formulacoes de aerossois sem clorofluorocarbonetos |
| IT1250691B (it) | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| NZ265054A (en) | 1993-04-02 | 1997-08-22 | Byk Gulden Lomberg Chem Fab | 16-hydroxy prednisolone cyclohexanecarboxaldehyde acetal derivatives |
| US5476411A (en) | 1993-07-16 | 1995-12-19 | Henkel Corporation | Aqueous composition for wet sanding of dried paint, plastics, and the like |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of drug patramulations |
| DE4434629C1 (de) | 1994-09-28 | 1996-06-27 | Byk Gulden Lomberg Chem Fab | Zusammensetzungen zur Behandlung von IRDS und ARDS |
| DE19541689A1 (de) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
| CA2217954C (en) | 1995-04-14 | 2005-02-15 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US6136839A (en) | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| WO1997011705A1 (en) | 1995-09-26 | 1997-04-03 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
| US6380222B2 (en) | 1996-10-11 | 2002-04-30 | Astrazeneca Ab | Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps |
| SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New teatment |
| FR2754712B1 (fr) | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | Compositions ophtalmiques |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US20020111495A1 (en) | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
| US6120752A (en) | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
| GB2329939A (en) | 1997-06-26 | 1999-04-07 | Glaxo Group Ltd | Self-lubricating valve stem for aerosol containers |
| US6470894B2 (en) | 1997-09-19 | 2002-10-29 | Thione International, Inc. | Glutathione, green tea, grape seed extract to neutralize tobacco free radicals |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| SE9801368D0 (sv) | 1998-04-20 | 1998-04-20 | Astra Ab | New use |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6264923B1 (en) | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| ATE283033T1 (de) | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| PL193616B1 (pl) | 1998-09-23 | 2007-02-28 | Altana Pharma Ag | Tetrahydropirydoetery |
| PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| US6124268A (en) | 1999-02-17 | 2000-09-26 | Natreon Inc. | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| US6302331B1 (en) | 1999-04-23 | 2001-10-16 | Battelle Pulmonary Therapeutics, Inc. | Directionally controlled EHD aerosol sprayer |
| WO2000064591A1 (en) | 1999-04-23 | 2000-11-02 | Battelle Memorial Institute | High mass transfer electrosprayer |
| JP2001048807A (ja) | 1999-08-04 | 2001-02-20 | Wakamoto Pharmaceut Co Ltd | 難溶性薬物を水に溶解してなる製剤 |
| DE19947234A1 (de) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| AR026072A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| GB0002336D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| GB0009607D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical compositions |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| TWI227231B (en) * | 2000-07-12 | 2005-02-01 | Novartis Ag | 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3 |
| FI20002177A0 (fi) | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| ATE320242T1 (de) | 2000-10-09 | 2006-04-15 | 3M Innovative Properties Co | Medizinische aerosolzusammensetzung |
| US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| WO2002038155A1 (en) | 2000-11-07 | 2002-05-16 | Merck & Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
| IL156308A0 (en) | 2000-12-22 | 2004-01-04 | Glaxo Group Ltd | Metered dose inhaler for salmeterol xinafoate |
| WO2003006310A1 (fr) | 2001-07-13 | 2003-01-23 | Tfe Techniques Et Fabrications Electroniques | Dispositif destine a indiquer acoustiquement a un plongeur equipe d'un scaphandre la pression de gaz de respiration dans le reservoir et/ou la pression hydrostatique |
| CA2464250C (en) | 2001-10-24 | 2008-08-05 | Frank-Christophe Lintz | Kit for the preparation of a pharmaceutical composition |
| EP1453743B1 (en) | 2001-11-17 | 2008-07-23 | Aventis Pharma Limited | Pharmaceutical product and method with an adsorbent |
| CA2467652A1 (en) | 2001-11-19 | 2003-05-30 | Altana Pharma Ag | Reversible proton pump inhibitors for the treatment of airway disorders |
| ITMI20020808A1 (it) | 2002-04-17 | 2003-10-17 | Chiesi Farma Spa | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione |
| BRPI0312377A8 (pt) | 2002-07-02 | 2015-12-15 | Altana Pharma Ag | Suspensão aquosa estéril contendo ciclesonida |
| ATE405275T1 (de) | 2002-12-12 | 2008-09-15 | Nycomed Gmbh | Kombinationsarzneimittel aus r,r-formoterol und ciclesonide |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| CA2538419C (en) | 2003-09-16 | 2012-07-03 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
-
2004
- 2004-09-15 CA CA2538419A patent/CA2538419C/en not_active Expired - Fee Related
- 2004-09-15 US US10/571,311 patent/US8371292B2/en active Active
- 2004-09-15 AU AU2004271744A patent/AU2004271744B2/en active Active
- 2004-09-15 EP EP04766791.0A patent/EP1670482B2/en active Active
- 2004-09-15 WO PCT/EP2004/052172 patent/WO2005025578A1/en active Application Filing
- 2004-09-15 JP JP2006525842A patent/JP5618452B2/ja active Active
- 2004-09-15 PT PT47667910T patent/PT1670482E/pt unknown
- 2004-09-15 ES ES04766791T patent/ES2452691T5/es active Active
- 2004-09-15 DK DK04766791.0T patent/DK1670482T4/da active
- 2004-09-15 PL PL04766791.0T patent/PL1670482T5/pl unknown
-
2012
- 2012-06-18 JP JP2012137341A patent/JP2012197306A/ja active Pending
-
2013
- 2013-01-18 US US13/744,962 patent/US20130143849A1/en not_active Abandoned
-
2014
- 2014-03-18 HR HRP20140257TT patent/HRP20140257T4/hr unknown
-
2019
- 2019-06-13 US US16/440,557 patent/US20190290661A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/447,302 patent/US20220241297A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004271744B2 (en) | 2010-07-29 |
| DK1670482T4 (da) | 2022-08-22 |
| CA2538419A1 (en) | 2005-03-24 |
| US8371292B2 (en) | 2013-02-12 |
| EP1670482A1 (en) | 2006-06-21 |
| JP2007505829A (ja) | 2007-03-15 |
| US20190290661A1 (en) | 2019-09-26 |
| EP1670482B1 (en) | 2013-12-25 |
| CA2538419C (en) | 2012-07-03 |
| US20220241297A1 (en) | 2022-08-04 |
| WO2005025578A1 (en) | 2005-03-24 |
| ES2452691T3 (es) | 2014-04-02 |
| PT1670482E (pt) | 2014-03-12 |
| JP5618452B2 (ja) | 2014-11-05 |
| AU2004271744A1 (en) | 2005-03-24 |
| PL1670482T3 (pl) | 2014-05-30 |
| PL1670482T5 (pl) | 2022-10-03 |
| US20070025923A1 (en) | 2007-02-01 |
| HRP20140257T1 (hr) | 2014-04-25 |
| ES2452691T5 (es) | 2022-09-14 |
| JP2012197306A (ja) | 2012-10-18 |
| DK1670482T3 (en) | 2014-03-17 |
| US20130143849A1 (en) | 2013-06-06 |
| EP1670482B2 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140257T4 (hr) | Uporaba ciklesonida za liječenje bolesti dišnih puteva | |
| ES2284732T3 (es) | Derivados de indanilo para tratar enfermedades de las vias respiratorias. | |
| Edsbäcker et al. | Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? | |
| NO328698B1 (no) | Anvendelse av mometasonfuroat for fremstilling av et torrpulverinhaleringsmedikament for behandling av sykdommer i de ovre eller nedre luftveier eller lunger | |
| NZ541997A (en) | Medicament comprising a highly potent long-lasting beta2-agonist in combination with a corticosteroid | |
| KR19990071975A (ko) | 신규한복합조성물 | |
| CN107998109A (zh) | 药物组合物 | |
| JP2007505829A5 (hr) | ||
| ES2426957T3 (es) | Procedimiento de tratamiento de rinosinusitis aguda | |
| Edsbäcker | Pharmacological factors that influence the choice of inhaled corticosteroids | |
| SK284252B6 (sk) | Použitie inhibítora H+, K+ -ATPáz a glukokortikoidu v terapii a farmaceutická kompozícia s ich obsahom | |
| Mealy et al. | Ciclesonide | |
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| Pavord et al. | Pharmacokinetic optimisation of inhaled steroid therapy in asthma | |
| JP2007533706A5 (hr) | ||
| JP2007533706A (ja) | 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用 | |
| Ringdal et al. | Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients | |
| WO2001012191A2 (en) | Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid | |
| Williams | Corticosteroid aerosols for the treatment of asthma | |
| ES2365533T3 (es) | Combinación de andolast / glucocorticoides. | |
| Catherin et al. | SAFETY, EFFICACY AND MANAGEMENT OF ASTHMA WITH ICS/LABA THERAPY: A REVIEW | |
| Maxwell et al. | Beclomethasone Dipropionate | |
| JP2013056925A (ja) | アンドラスト／グルココルチコイドの併用 |